Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eosinophil chemoattractants generated in vivo

T J Williams1, D A Griffiths-Johnson, P J Jose

  • 1Department of Applied Pharmacology, National Heart and Lung Institute, London, United Kingdom.

Agents and Actions. Supplements
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.

Alimentary pharmacology & therapeutics·2017
Same author

Commentary: risk of colorectal adenomas and advanced neoplasia in Hispanic, black and white patients.

Alimentary pharmacology & therapeutics·2012
Same author

Progressive shortness of breath.

BMJ (Clinical research ed.)·2009
Same author

Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum.

Thorax·2008
Same author

Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.

The Cochrane database of systematic reviews·2006
Same author

Selective suppression of leukocyte recruitment in allergic inflammation.

Memorias do Instituto Oswaldo Cruz·2005
Same journal

Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.

Agents and actions. Supplements·1998
Same journal

Immunomodulation of Crohn's disease by interleukin-10.

Agents and actions. Supplements·1998
Same journal

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

Agents and actions. Supplements·1998
Same journal

Symposium new drugs for inflammatory, allergic and immunologic disease.

Agents and actions. Supplements·1998
Same journal

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.

Agents and actions. Supplements·1998
Same journal

A role for inflammatory cytokines in the productive activation of antigen-specific CD4+ T-cells.

Agents and actions. Supplements·1998
See all related articles

Eosinophils are key inflammatory cells in asthma, but their exact role is debated. Targeting eosinophil chemoattractant receptors offers a potential therapeutic strategy for long-term asthma management.

Area of Science:

  • Immunology
  • Pulmonology
  • Allergy Research

Background:

  • Eosinophils are the primary inflammatory cells in asthmatic lungs, implicated in lung dysfunction.
  • The precise role of eosinophils in asthma pathogenesis remains controversial.
  • Eosinophils' defensive function is primarily against helminth parasites, not essential for microbial defense like neutrophils.

Purpose of the Study:

  • To identify endogenous chemoattractants responsible for eosinophil accumulation in asthma.
  • To lay the groundwork for developing chemoattractant receptor antagonists.
  • To explore selective leukocyte suppression as a therapeutic approach for asthma.

Main Methods:

  • Review of current literature on eosinophil accumulation and activation in the lung.

Related Experiment Videos

  • Focus on identifying chemoattractants generated in the asthmatic lung.
  • Research into blocking receptors for these chemoattractants.

    • Main Results:

    • The study highlights the need to identify specific eosinophil chemoattractants.
    • It emphasizes the potential for targeting chemoattractant receptors.
    • Recent attempts to identify these chemoattractants are discussed.

    Conclusions:

    • Suppressing eosinophil accumulation is a viable therapeutic strategy for asthma.
    • Identifying chemoattractants is a crucial first step toward developing targeted therapies.
    • Development of chemoattractant receptor antagonists could lead to selective suppression of eosinophils.